A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis

Phase 3

Recruiting

• Conditions: Postmenopausal Women Osteoporosis
• Interventions: Drug: 9MW0311; Drug: Prolia®

• Registration Number: NCT06804590
• Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Brief Summary

This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with osteoporosis at high risk for fracture.

Detailed Description

278 patients are randomized 1:1 to receive 9MW0311 and Prolia® every 6 months for 12 months. The primary efficacy endpoint is the percentage change from baseline in BMD at the lumbar spine(LS) in month 12.

Study Timeline

• Study Start: 2024-11-16
• Study First Submitted: 2024-12-09
• Status Verified: 2025-01
• Study First Submitted QC: 2025-01-27
• Last Update Submitted: 2025-01-27
• Study First Posted: 2025-02-03
• Last Update Posted: 2025-02-03
• Primary Completion: 2026-04-30
• Study Completion: 2026-07-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 278

Inclusion Criteria

• Women who can walk freely (≥50 and ≤80 years);
• As measured by DXA, the absolute value of BMD at lumbar spine, femoral neck or total hip was -4.0<T value ≤-2.5;
• Subjects must have at least one of the following other risk factors: 1) history of previous fragility fractures; 2) Either or both parents have a history of hip fragility fracture; 3) Increased bone turnover rate during screening; 4) Low body weight; 5) Old age(≥70); 6) Currently smoking.
• The duration of spontaneous amenorrhea was >2 years or >2 years after bilateral oophorectomy. If the status of bilateral oophorectomy is unknown or if the ovaries are preserved after hysterectomy, follicle stimulating hormone (FSH) levels >40mIU/mL may be used to confirm the status of postoperative menopause.

Exclusion Criteria

• Bone/metabolic disease

• Hyperparathyroidism or hypoparathyroidism

• Thyroid condition: Hyperthyroidism or hypothyroidism

• Rheumatoid arthritis

• Malignant tumors

• Malabsorption syndrome

• Liver cirrhosis, active hepatitis B or hepatitis C, and unstable liver disease; serum aspartate aminotransferase and alanine aminotransferase ≥ 2.0 times the upper limit of normal (ULN); alkaline phosphatase or total bilirubin ≥ 1.5 ULN;

• Renal disease - severe impairment of kidney function

• Clinically significant cardiovascular and cerebrovascular diseases (such as myocardial infarction, unstable angina or stroke, NYHA class III or IV heart failure in the 12 months prior to screening) and hematopoietic system disease judged by the investigator;

• Hypercalcemia or hypocalcemia ;

• vitamin D deficiency (25-hydroxyvitamin D, 25OHD <20 ng/mL);

• Oral or dental diseases: previous or current evidence of mandibular osteomyelitis or osteonecrosis; Acute dental or mandibular disease requiring oral surgery; Planning invasive dental surgery; Failure to recover from dental or oral surgery;

• Use of intravenous bisphosphonates within the previous 2 years;

• oral bisphosphonates (used for at least 2 years, or used for less than 2 years but more than 3 months, with the last use occurring <1 year before the screening);

• Use of any of the following drugs within 6 weeks prior to screening that may affect bone metabolism:

  1. parathyroid hormone (PTH) or PTH derivatives, such as teriparatide;
  2. anabolic hormones or testosterone;
  3. glucocorticoids (equivalent dose more than 5mg/ day of prednisone and continuous use for more than 10 days);
  4. Selective estrogen receptor modulators (SERMs), such as raloxifene;
  5. Menopausal hormone therapy (such as estrogen, estrogen + progesterone, tibolone);
  6. Active vitamin D and its analogues (cumulative use of more than 30 days);
  7. Other bone-active drugs include antiepileptic drugs (except benzodiazepines) and heparin;
  8. Long-term systemic use of ketoconazole, adrenocorticotropin (ACTH), aluminum, lithium, protease inhibitors, methotrexate, gonadotropin releasing hormone agonists;
  9. Chinese patent medicines for osteoporosis related treatment are clearly described in the instructions, such as Xianling Gubao capsule (tablet), Gushukang capsule (granule), Jintiange capsule and Qianggu capsule."

• History of more than two vertebral fractures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
9MW0311	9MW0311	9MW0311 Denosumab injection(60 mg)
Prolia®	Prolia®	Prolia® Denosumab injection(60 mg)

Primary Outcome Measures

Name	Time	Method
Percent Change From Baseline in lumbar spine(LS)-BMD at Week 53 （Month 12)	Baseline and 12 months	Percent Change From Baseline in LS-BMD at Week 53 （Month 12)

Secondary Outcome Measures

Name	Time	Method
Percent Change From Baseline in LS-BMD at Week 27 （Month 6)	Baseline and Month 6	Percent Change From Baseline in LS-BMD at Week 27 （Month 6)
Percent change in BMD at the total hip, femoral neck from Baseline up to week 27 (Month 6) and Week 53 (Month 12 )	Baseline, Month6 and Month 53	Percent change in BMD at the total hip, femoral neck from Baseline up to week 27 (Month 6) and Week 53 (Month 12 )
Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum type I procollagen N-terminal propeptide (s-PINP) from Baseline up to 12 months	Baseline, Month1, Month3, Month6, Month9 and Month 12	Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum type I procollagen N-terminal propeptide (s-PINP) from Baseline up to 12 months
Proportion of subjects with new fragility fractures (e.g., vertebrae, hip, non-vertebrae)	From baseline to Month12	Proportion of subjects with new fragility fractures (e.g., vertebrae, hip, non-vertebrae)
Number of participants with AE, SAE, with abnormal vital signs, abnormal physical examination findings, abnormal oral examination findings, abnormal laboratory tests results and abnormal 12-lead ECG readings	From baseline to Month12	AE, SAE, vital signs, physical examination, oral examination, laboratory examination (blood routine, urine routine/urine sediment, blood biochemistry, coagulation function), 12-lead ECG
ADA positive rate and ADA titer (if applicable)	Baseline and Month 1, Month3, Month6, Month12	ADA positive rate and ADA titer (if applicable)
NAb positive rate (if applicable)	Baseline and Month 1, Month3, Month6, Month12	NAb positive rate (if applicable)

Trial Locations

Locations (1)

Mabwell (Shanghai) Bioscience Co., Ltd.; 🇨🇳 Beijing, China